Two elderly patients diagnosed with Pseudomonas aeruginosa urinary tract infections were treated with oral norfloxacin in the recommended dose of 400 mg q12h. Initially, antimicrobial susceptibility data indicated the organisms were sensitive to norfloxacin. Six to eight days into therapy urine cultures became positive for P. aeruginosa once again; this time, however, susceptibility reports indicated the organisms were now resistant to norfloxacin. Since cross-resistance among norfloxacin, other quinolones, and cephalosporins can occur, we recommend repeated urine cultures during and after norfloxacin therapy in elderly patients with complicated P. aeruginosa urinary tract infections.
Get full access to this article
View all access options for this article.
References
1.
RowenRCMichelDJThompsonJC. Norfloxacin: Clinical pharmacology and clinical use. Pharmacotherapy1987; 7: 92–110.
2.
RonaldARTurckMPetersdorfRG. A critical evaluation of nalidixic acid in urinary tract infections. N Engl J Med1966; 275: 1081–9.
3.
StameyTABragonjeJ. Resistance to nalidixic acid. A misconception due to underdosage. JAMA1976; 236: 1857–60.
4.
Product monograph. Noroxin (norfloxacin). West Point, PA: Merck Sharp & Dohme, October 1986.
5.
CrumplinGCKenwrightMHirstt. Investigations into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother1984; 13 (suppl B): 9–23.
6.
DuckworthGJWilliamsJD. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid. J Antimicrob Chemother1984; 13 (suppl B): 33–8.
HooperDCWolfsonJSSouzaKS. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother1986; 29: 639–44.
9.
SandersCCSandersWEGoeringRVWernerV. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother1984; 26: 797–801.
10.
HiraiFSuzueSIrikuraTIyobeSMitsuhashiS. Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother1987; 31: 582–6.
11.
TenneyJHMaackRWChippendaleGR. Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrob Agents Chemother1983; 23: 188–9.
12.
BarryALJonesRN. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother1984; 25: 775–7.
13.
CullmanWSteiglitzMBaarsBOpferkuchW. Comparative evaluation of recently developed quinolone compounds with a note on the frequency of resistant mutants. Chemotherapy1985; 31: 19–28.
14.
PiffarettiJCDemartaALeidi-BullaLPeduzziR. In vitro emergence of Escherichia coli and Pseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid. Eur J Clin Microbiol1983; 2: 600–1.
15.
ShahPMOttradMStilleW. In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid, and pipemidic acid. Eur J Clin Microbiol1983; 2: 272–4.
16.
ArrigoGCavaliereGD'AmicoGPassarellaEBroccaliG. Pharmacokinetics of norfloxacin in chronic renal failure. Int J Clin Pharmacol Ther Toxicol1985; 23: 491–6.
